Comparative Bioavailability of Intranasal Epinephrine

Conditions: Anaphylaxis; Anaphylactic Reaction Interventions: Drug: A: Epinephrine injection; Drug: B: FMXIN002 3.6mg; Drug: C: FMXIN002 4.0mg Sponsors: Nasus Pharma; Hadassah Medical Organization; Medistat Ltd., Israel; Pharma Medica Research, Inc. Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials